Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wenzel, Patrick
NCT05174650 / 2020-004938-38: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements	Active, not recruiting	2	27	Europe	Atezolizumab, Tecentriq, Derazantinib, ARQ 087	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, ROCHE Pharma AG, Basilea Pharmaceutica International Ltd.	Intrahepatic Cholangiocarcinoma	12/25	08/26